

# Anita D'Souza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2918327/publications.pdf>

Version: 2024-02-01

167  
papers

4,141  
citations

159358

30  
h-index

138251

58  
g-index

172  
all docs

172  
docs citations

172  
times ranked

5057  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
2	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	0.8	212
3	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210
4	Current Use and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1417-1421.	2.0	205
5	The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. <i>Blood</i> , 2011, 118, 4663-4665.	0.6	176
6	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	0.8	163
7	Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. <i>Blood</i> , 2012, 120, 56-62.	0.6	133
8	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. <i>JAMA Oncology</i> , 2018, 4, 343.	3.4	130
9	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2901-2912.	0.8	124
10	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
11	Granulocyte Colony-“Stimulating Factor Administration: Adverse Events. <i>Transfusion Medicine Reviews</i> , 2008, 22, 280-290.	0.9	98
12	Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 71-75.	1.4	74
13	Impact of pre-“transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	2.0	73
14	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017, 123, 3141-3149.	2.0	65
15	Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. <i>Neurology</i> , 2015, 84, 1981-1987.	1.5	61
16	Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2291-2301.	1.4	61
17	Association Between Ipilimumab and Celiac Disease. <i>Mayo Clinic Proceedings</i> , 2013, 88, 414-417.	1.4	58
18	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55

#	ARTICLE	IF	CITATIONS
19	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49
20	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.4	47
21	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	2.0	47
22	Progressive Multifocal Leukoencephalopathy in Chronic Lymphocytic Leukemia: A Report of Three Cases and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, E1-E9.	0.2	44
23	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	2.0	44
24	Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 43-44.	0.6	44
25	Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
26	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	1.7	38
27	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
28	Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
29	The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. <i>Translational Psychiatry</i> , 2021, 11, 58.	2.4	36
30	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. <i>Cancer Cell</i> , 2022, 40, 340-342.	7.7	35
31	Localized insulin-derived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. <i>American Journal of Hematology</i> , 2012, 87, E131-2.	2.0	34
32	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
33	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
34	Multiple myeloma and COVID-19. <i>Leukemia</i> , 2020, 34, 1961-1963.	3.3	29
35	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2466-2470.	2.5	29
36	Localized Tongue Amyloidosis: A Single Institutional Case Series. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 149, 240-244.	1.1	28

#	ARTICLE	IF	CITATIONS
37	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018, 18, 593.	1.1	28
38	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
39	Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial. <i>EClinicalMedicine</i> , 2020, 23, 100361.	3.2	27
40	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
41	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	0.6	26
42	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1955-1960.	2.0	24
43	Plerixafor and Abbreviated-Course Granulocyte Colony-Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1926-1931.	2.0	23
44	Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 10-14.	0.6	23
45	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
46	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23
47	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, 34.	2.8	22
48	Signaling Pathways and Emerging Therapies in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 156-164.	1.2	20
49	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 335-342.	2.0	20
50	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
51	Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 65-70.	0.6	19
52	Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. <i>American Journal of Hematology</i> , 2013, 88, 577-580.	2.0	18
53	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
54	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 379-386.	0.2	17

#	ARTICLE	IF	CITATIONS
55	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 165-172.	0.2	17
56	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 33-38.	0.5	17
57	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
58	Salvage second transplantation in relapsed multiple myeloma. <i>Leukemia</i> , 2021, 35, 1214-1217.	3.3	17
59	Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 225-231.	1.3	17
60	Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 1253-1258.	1.9	16
61	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 56.	2.8	15
62	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15
63	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.	2.0	14
64	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1193-1202.	2.0	14
65	Recent advances in understanding and treating immunoglobulin light chain amyloidosis. <i>F1000Research</i> , 2018, 7, 1348.	0.8	14
66	Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 617.e1-617.e7.	0.6	14
67	Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 431-439.	0.7	13
68	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
69	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 893-901.	2.0	13
70	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	0.6	13
71	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	3.3	13
72	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	0.6	13

#	ARTICLE	IF	CITATIONS
73	A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3) Tj ETQq1 1 0.7843141gBT /Over	2.8	12
74	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Network Open, 2019, 2, e196476.	2.8	12
75	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biology of Blood and Marrow Transplantation, 2019, 25, 1099-1106.	2.0	12
76	Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. American Journal of Hematology, 2023, 98, 140-147.	2.0	12
77	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11
78	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 2011-2017.	2.0	11
79	Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. Cancer, 2020, 126, 2679-2686.	2.0	11
80	Autonomic nervous system control of multiple myeloma. Blood Reviews, 2021, 46, 100741.	2.8	11
81	Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. American Journal of Hematology, 2015, 90, E212-3.	2.0	10
82	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, e33-e38.	2.0	10
83	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biology of Blood and Marrow Transplantation, 2020, 26, 1288-1297.	2.0	10
84	The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 111-118.	1.4	10
85	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	0.6	9
86	CYP2C19*17 genetic polymorphismâ€”an uncommon cause of voriconazole treatment failure. Diagnostic Microbiology and Infectious Disease, 2015, 83, 46-48.	0.8	8
87	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1295-1302.	2.0	8
88	Pharmacokinetics of High-Dose Propylene Glycolâ€”Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1610-1614.	2.0	8
89	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. British Journal of Haematology, 2020, 191, 442-452.	1.2	8
90	Racial disparities in patients diagnosed with light chain (AL) amyloidosis. Blood Cancer Journal, 2021, 11, 72.	2.8	8

#	ARTICLE	IF	CITATIONS
91	Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. <i>Cancer</i> , 2021, 127, 4233-4239.	2.0	8
92	Waldenström macroglobulinaemia: the key questions. <i>British Journal of Haematology</i> , 2013, 162, 295-303.	1.2	7
93	Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cell Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1395-1398.	2.0	7
94	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1773-1780.	2.0	7
95	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	1.3	7
96	Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 105-111.	0.6	7
97	Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 805-813.	2.0	7
98	What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2423-2425.	0.8	7
99	Nutrition perceptions, needs and practices among patients with plasma cell disorders. <i>Blood Cancer Journal</i> , 2022, 12, 70.	2.8	7
100	Clinically significant anti-A1 in a presumed ABO-identical hematopoietic stem cell transplant recipient: a case report. <i>Transfusion</i> , 2013, 53, 202-205.	0.8	6
101	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 305-311.e2.	0.2	6
102	Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1053-1062.	0.6	6
103	Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 129-134.	1.4	6
104	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 2791-2801.	2.0	6
105	Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. <i>Blood Cancer Journal</i> , 2021, 11, 29.	2.8	6
106	Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study. <i>Quality of Life Research</i> , 2022, 31, 1083-1092.	1.5	6
107	New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 768-770.	2.0	5
108	Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1079-1082.	1.3	5

#	ARTICLE	IF	CITATIONS
109	Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. <i>Leukemia and Lymphoma</i> , 2020, 61, 3484-3492.	0.6	5
110	Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma. <i>Blood</i> , 2019, 134, 782-782.	0.6	5
111	Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. <i>Blood Cancer Journal</i> , 2022, 12, 17.	2.8	5
112	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3991-3995.	2.5	5
113	Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a <scp>BMT CTN</scp> 0102 correlative study. <i>British Journal of Haematology</i> , 2017, 178, 816-819.	1.2	4
114	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2229-2236.	2.0	4
115	Reporting of race and ethnicity at an international haematology conference. <i>British Journal of Haematology</i> , 2020, 191, e107-e109.	1.2	4
116	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
117	Trends in the use of therapeutic plasma exchange in multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2020, 35, 307-315.	0.7	4
118	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e468-e473.	0.2	4
119	Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation. <i>American Journal of the Medical Sciences</i> , 2021, 362, 72-77.	0.4	4
120	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	1.3	4
121	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	4
122	Localized Lymph Node Light Chain Amyloidosis. <i>Case Reports in Hematology</i> , 2015, 2015, 1-4.	0.3	3
123	An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. <i>Journal of Clinical Apheresis</i> , 2019, 34, 686-691.	0.7	3
124	Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study. <i>Blood</i> , 2014, 124, 193-193.	0.6	3
125	Trends in Pre- and Post-Transplant Therapies Prior to First Autologous Hematopoietic Cell Transplantation Among Patients with Multiple Myeloma in the United States, 2004-2014. <i>Blood</i> , 2016, 128, 677-677.	0.6	3
126	Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	3



#	ARTICLE	IF	CITATIONS
127	Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. <i>American Journal of Hematology</i> , 2022, 97, 1170-1177.	2.0	3
128	Lymphoma-associated versus lymphocytic-variant hypereosinophilia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2103-2104.	0.6	2
129	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	1.4	2
130	Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 87-88.	1.4	2
131	Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 667054.	2.2	2
132	Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 396-396.	0.6	2
133	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 295-298.	1.3	2
134	The Hematologist's Role in Amyloidosis Management: Disease Awareness, Diagnostic Workup, and Practice Patterns. <i>Blood</i> , 2020, 136, 28-29.	0.6	2
135	Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1598-1600.	0.8	1
136	Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Blood</i> , 2018, 132, 832-832.	0.6	1
137	Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen. <i>Blood</i> , 2019, 134, 2023-2023.	0.6	1
138	Drug-Induced Amyloidosis: A Proteomic Insight Into 52 Cases. <i>Blood</i> , 2013, 122, 1871-1871.	0.6	1
139	Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. <i>Blood</i> , 2014, 124, 2447-2447.	0.6	1
140	Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age. <i>Blood</i> , 2016, 128, 3456-3456.	0.6	1
141	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. <i>Blood</i> , 2021, 138, 4759-4759.	0.6	1
142	Prevalence of Race/Ethnicity Reporting in Light Chain (AL) Amyloidosis Clinical Research in the USA. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 644-650.	1.8	1
143	MGIP, MGUS, and the PROMISE of meaning in small things. <i>Lancet Haematology</i> , 2022, 9, e315-e317.	2.2	1
144	Important questions for the malignant hematologist to consider when designing or evaluating a study with patient-reported outcome measures ( <sc>PROMs</sc> ). <i>European Journal of Haematology</i> , 2022, , .	1.1	1

#	ARTICLE	IF	CITATIONS
145	In Reply. <i>Oncologist</i> , 2020, 25, e744-e745.	1.9	0
146	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e775-e781.	0.2	0
147	Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. <i>Leukemia Research</i> , 2021, 109, 106648.	0.4	0
148	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2011, 118, 3101-3101.	0.6	0
149	Replication of Candidate Gene Single Nucleotide Polymorphisms (SNPs) Previously Reported As Associated with Venous Thromboembolism (VTE). <i>Blood</i> , 2011, 118, 1238-1238.	0.6	0
150	Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) for hematopoietic progenitor cell (HPC) mobilization in AL amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8606-8606.	0.8	0
151	A Statistical Model for Predicting Neutropenic Fever. <i>Blood</i> , 2014, 124, 5258-5258.	0.6	0
152	A statistical model for predicting neutropenic fever.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18050-e18050.	0.8	0
153	Association of abnormal molecular markers with clonal plasma cell burden in light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8063-8063.	0.8	0
154	Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL). <i>Blood</i> , 2016, 128, 5192-5192.	0.6	0
155	Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8022-8022.	0.8	0
156	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8012-8012.	0.8	0
157	Monoclonal Gammopathy of Renal Significance. , 2018, 15, .		0
158	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. <i>Blood</i> , 2018, 132, 3544-3544.	0.6	0
159	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. <i>Blood</i> , 2018, 132, 617-617.	0.6	0
160	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018, 132, 1998-1998.	0.6	0
161	Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. <i>Blood</i> , 2021, 138, 4091-4091.	0.6	0
162	Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 36-37.	0.6	0

#	ARTICLE	IF	CITATIONS
163	EPR22-115: Reporting of Race and Ethnicity in AL Amyloid Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, EPR22-115.	2.3	0
164	Rap1A, Rap1B, and $\beta$ -Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.. Yale Journal of Biology and Medicine, 2022, 95, 45-56.	0.2	0
165	Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.. Journal of Clinical Oncology, 2022, 40, 8057-8057.	0.8	0
166	Incorporating patient-reported outcome data into a hematopoietic cell transplant survival calculator.. Journal of Clinical Oncology, 2022, 40, 7045-7045.	0.8	0
167	Kinetics of humoral immunodeficiency with bispecific antibody therapy in multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8049-8049.	0.8	0